Hépatite C: Prévention, dépistage et traitement pour les usagers de drogues
Signez cette pétition pour demander un meilleur accès à la prévention, au dépistage et au traitement de l'hépatite C pour les usagers de drogues en Europe! Pour en savoir plus, en Anglais, veuillez lire les informations ci-dessous.
Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.
Manifesto
Hepatitis C: Access to Prevention, Testing, Treatment and Care for People who Use Drugs
Hepatitis C is a Major Global Public Health Problem! THE TIME TO ACT IS NOW!
Hepatitis C statistics and policy facts:
- 150 million people worldwide are living with chronic hepatitis C virus (HCV), of those infected, nine million are living in the European region.
- The burden of HCV is concentrated among people who inject drugs (PWID) in Europe, with HCV antibody prevalence ranging from 80% in Finland to over 90% in Estonia. The World Health Organization (WHO) has identified people who inject drugs as a key target group for HCV prevention and treatment.
- In January 2014, the first all oral HCV treatments providing cure rates of up to 98% in clinical trials were approved by the European Commission.
- In spite of European guidelines recommending treatment access people who use drugs still face considerable barriers to, and are frequently denied, access to the newly approved HCV treatment regimens.
- The scale-up of HCV treatment access to people who inject drugs has the potential to significantly reduce the number of new infections and the prevalence in the population, acting as an effective preventative measure.
Major European and international agencies working in, or involved with health and drugs, such as WHO, UNODC, UNAIDS, EMCDDA and ECDC consider viral hepatitis, especially among people who inject drugs, a serious public health problem.
Click here to sign the petition.
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.